Cerevel Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2018-01-01
- Employees
- -
- Market Cap
- $8.1B
- Website
- https://www.cerevel.com/
A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06435923
- Locations
- 🇺🇸
Austin, Texas, Austin, Texas, United States
A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT06366243
- Locations
- 🇺🇸
Dilworth, Minnesota, Dilworth, Minnesota, United States
A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06301971
- Locations
- 🇺🇸
Austin, Texas, Austin, Texas, United States
A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT05965219
- Locations
- 🇺🇸
Overland Park, Kansas, Overland Park, Kansas, United States
A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT05933187
- Locations
- 🇺🇸
Overland Park, Kansas, Overland Park, Kansas, United States
The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT05915546
- Locations
- 🇺🇸
Dilworth, Minnesota, Dilworth, Minnesota, United States
Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT05824143
- Locations
- 🇺🇸
Orlando, Florida, Orlando, Florida, United States
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT05610189
- Locations
- 🇺🇸
South Miami, Florida, South Miami, Florida, United States
🇺🇸Hollywood, Florida, Hollywood, Florida, United States
🇺🇸Farmington Hills, Michigan, Farmington Hills, Michigan, United States
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT05581823
- Locations
- 🇺🇸
Madison, Wisconsin, Madison, Wisconsin, United States
Positron Emission Tomography (PET) Trial to Evaluate Target Occupancy of CVL-354 at Kappa and Mu Opioid Receptors in Brain Following Oral Dosing
Phase 1
Completed
- Conditions
- Opioid Use Disorder
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 19
- Registration Number
- NCT05547542
- Locations
- 🇺🇸
New Haven, Connecticut, New Haven, Connecticut, United States
🇺🇸Yale PET Center, New Haven, Connecticut, United States
© Copyright 2025. All Rights Reserved by MedPath